GovChime
Awarded

Clinical Trial Materials for Virus Vaccines

Awarded tounder 75N93021D00018 (source: SAM.gov award notice)• $24.5M

Overview

Posted
February 24, 2021
Notice type
Award Notice
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NIH NIAID DEA OA OFC ACQUISITIONS
Place of performance
Bethesda, MD, 20892
Last updated
Oct 9, 2026
Award date
Feb 23, 2021
Award amount (SAM.gov award notice)
$24.5M

Identifiers

Solicitation number
75N93020R00008
Notice ID
d1dc46f5812b40b6bb3dad7c1ae42c52
Award number (PIID)
75N93021D00018

Description

Background and Introduction The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) is dedicated to improving global human health through the rigorous pursuit of effective vaccines for human diseases. One of the key components of NIAIDs mission involves the rapid advancement of promising vaccine candidates from the laboratory to the clinic. The Division of Intramural Research (DIR) within NIAID has a long history of studying the etiology and pathogenesis of infectious viral diseases, and of developing effective means of preventing or treating these diseases. NIAID DIR has advanced to clinical trials multiple vaccine candidates, including both live-attenuated and inactivated virus formats. These formats have several advantages, including the ability to elicit a strong immune response with only one administration of vaccine. A primary objective of DIR remains the development of safe and effective vaccines against several disease-causing viruses including influenza, respiratory syncytial virus (RSV) and related pediatric respiratory viruses, dengue virus (DENV), and West Nile virus (WNV). In recent years, one of the major areas of DIR's continuing research is the development of live-attenuated vaccine candidates effective against newly identified or emerging viruses, such as Zika virus (ZIKV) or the virus that causes COVID-19 (SARS-CoV-2). The capability to rapidly advance candidates for emerging viruses into clinical testing is now a critical component for NIAID DIRs mission. This acquisition is for a single-award, Indefinite Delivery/Indefinite Quantity (IDIQ) contract that will be funded on a Task Order (TO) basis. The purpose of this acquisition is to establish an appropriate current Good Manufacturing Practice (cGMP) Contract Manufacturing Organization (CMO) to support rapid vaccine development by manufacturing vaccine Clinical Trial Materials (CTM) for trials of live-attenuated virus or inactivated virus vaccine candidates. cGMP is a Food and Drug Administration (FDA) regulation. Vaccine ancillaries or other biologics required to advance to clinical trials, such as virus challenge stocks, diluents, cell lines for use in the production of the vaccines, test materials, etc., are also within scope. The CMO shall have capability to produce viruses in both cell culture and specific-pathogen-free (SPF) eggs at scale appropriate for Phase 1 and 2 clinical trials. Based on extensive history, NIAID has existing processes for manufacturing the virus suspensions (candidate vaccine or challenge stock lot). The Contractor will produce, purify, process, fill, and flash freeze the virus suspensions as directed by NIAID, including any needed process qualifications. All activities required to comply with aseptic cGMP production and product management such as documentation, testing, storage, shipping, stability testing, etc. will also be required as specified under the Statement of Work and associated Task Orders. The contract will support work components in the following areas: Production of Virus Suspensions in Cell Culture Production of Influenza Virus Suspensions in the Allantoic Cavity of Embryonated Eggs Production of Qualified Cell Lines Process Development. Qualification of other vaccine components. For this solicitation, the NIAID requires proposals to be submitted via Online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov and then click on "How to Submit." To submit online using eCPS, offerors must have a valid NIH electronic Research Administration (eRA) Commons account, which provides authentication and serves as a vehicle for secure transmission of documents and communication with the NIAID. The eRA Commons registration process may take up to 6 weeks. For more information, please see https://grants.nih.gov/grants/how-to-apply-application-guide/prepare-to-apply-and-register/register.htm Inquiries Please direct all inquiries to: Primary Contact: Mr. Uju Obii-Obioha National Institute of Allergy and Infectious Diseases (NIAID) Telephone: 301-761-6540 Email: uju.obii-obioha@nih.gov. Secondary Contact: Mr. Sevag Kasparian National Institute of Allergy and Infectious Diseases Telephone: 240-669-5177 Email: sevag.kasparian@nih.gov.

Full description on SAM.gov

Award Overview

Award Number

75N93021D00018

Award Amount (SAM.gov award notice)

$24.5M

Award Date

Feb 23, 2021

Awardee

Awardee UEI

NAPSK1UAMAE5

Awardee CAGE Code

5A148

Original Solicitation

Notice ID: d1dc46f5812b40b6bb3dad7c1ae42c52

Posted Date: Feb 24, 2021

Original Response Deadline: Not specified

Task Orders Under This IDV

Top 10 by total obligated

10
  • 75N93025F00001
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $5.2MSigned Sep 10, 2026
  • 75N93025F00001
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $5.2MSigned Jan 30, 2026
  • 75N93025F00001
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $4.7MSigned Sep 29, 2025
  • 75N93022F00003
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $2.6MSigned Jul 22, 2024
  • 75N93022F00003
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $2.0MSigned Aug 14, 2024
  • 75N93022F00003
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $2.0MSigned Apr 30, 2026
  • 75N93022F00003
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $1.4MSigned Aug 31, 2023
  • 75N93022F00003
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $1.4MSigned Sep 14, 2022
  • 75N98026F00004
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $1.0MSigned Aug 31, 2026
  • 75N93022F00002
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $629.8KSigned Jul 19, 2024

More From This Vendor

Top 5 most recent

5
  • 75N93025F00001
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $5.2MSigned Sep 10, 2026
  • 75N95C21P00043
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $7.8KSigned Sep 8, 2026
  • 75N98026F00004
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $1.0MSigned Aug 31, 2026
  • 75N98020P00712
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $24.0KSigned Aug 26, 2026
  • 75N98026F00003
    CHARLES RIVER LABORATORIES, INC.
    Department of Health and Human ServicesNAICS 541715
    $371.6KSigned Aug 18, 2026

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

No documents available.

Lifecycle

Solicitation:75N93020R00008
  1. Market Research
  2. Solicitation
  3. Awarded

This opportunity has been awarded.

  1. Market ResearchDec 16, 2019

    Clinical Trial Materials for Virus Vaccines

    Notice 63772cc13db24ebcbf18a1751fdefae5 on SAM.gov

  2. 2×
    SolicitationJun 8, 2020

    Clinical Trial Materials for Virus Vaccines

    Notice f82bee7a811f437389e713566257b07e on SAM.gov

  3. AwardedCurrentFeb 24, 2021

    Clinical Trial Materials for Virus Vaccines

    Notice d1dc46f5812b40b6bb3dad7c1ae42c52 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

75N93020R00008

Archive Date

Mar 10, 2021

Office Address

BETHESDA, MD, 20892